Physician profile
Daniel Warren Levine
NPI 1679584312
$5,001.55
in general payments reported to CMS, 2019-2025
16 companies · $297 in 2025
The $297 reported for 2025 was more than what 76% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $475 · 2021: $804 · 2022: $592 · 2023: $565 · 2024: $292 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $2,863.27 | 2019-2025 | Menopur |
| Abbvie INC. | $924.11 | 2019-2023 | |
| Exeltis, USA INC. | $243.26 | 2019-2023 | Slynd |
| Covidien Lp | $189.06 | 2019 | |
| Novo Nordisk INC | $179.78 | 2023-2025 | Wegovy |
| Coopersurgical, INC. | $160.14 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $124.14 | 2019 | |
| Alfasigma USA, INC. | $108.47 | 2020-2021 | |
| Emd Serono, INC. | $69.60 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $36.43 | 2019 | |
| Organon LLC | $24.74 | 2021 | |
| Therapeuticsmd, INC. | $19.30 | 2019 | |
| Lilly USA, LLC | $18.55 | 2024 | Zepbound |
| Sumitomo Pharma America, INC. | $15.97 | 2023 | Myfembree |
| Cook Medical LLC | $12.93 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mission Pharmacal Company | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Levine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.